Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Study sponsor: Nuvation Bio Inc. · NUVB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-06-11Actual
Enrollment · participants217Actual
Source updated2026-01-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.